



Office_NNP of_IN the_DT General_NNP Counsel_NNP
B-_NNP 277228_CD
June_NNP 24_CD ,_, 1997_CD
The_DT Honorable_NNP James_NNP M_NNP ._. Jeffords_NNP Chairman_NNP The_DT Honorable_NNP Edward_NNP M_NNP ._.
Kennedy_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Labor_NNP and_CC Human_NNP
Resources_NNPS United_NNP States_NNPS Senate_NNP
The_DT Honorable_NNP Thomas_NNP J_NNP ._. Bliley_NNP ,_, Jr_NNP ._. Chairman_NNP The_DT Honorable_NNP John_NNP
D_NNP ._. Dingell_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Commerce_NNP House_NNP of_IN
Representatives_NNPS
Subject_NNP :_: Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP
Administration_NNP :_: Substances_NNP Prohibited_NNP From_IN Use_NN in_IN Animal_NNP Food_NNP or_CC
Feed_NNP ;_: Animal_NNP Proteins_NNPS Prohibited_NNP in_IN Ruminant_NNP Feed_NNP
Pursuant_NNP to_TO section_NN 801_CD (_( a_DT )_) (_( 2_LS )_) (_( A_DT )_) of_IN title_NN 5_CD ,_, United_NNP States_NNPS Code_NNP ,_,
this_DT is_VBZ our_PRP$ report_NN on_IN a_DT major_JJ rule_NN promulgated_VBD by_IN the_DT Department_NNP of_IN
Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) ,_,
entitled_VBN "_'' Substances_NNP Prohibited_NNP From_IN Use_NN in_IN Animal_NNP Food_NNP or_CC Feed_NNP ;_:
Animal_NNP Proteins_NNPS Prohibited_NNP in_IN Ruminant_NNP Feed_NNP "_'' (_( RIN_NNP :_: 0910_CD -_: AA_NN 91_CD )_) ._. We_PRP
received_VBD the_DT rule_NN on_IN June_NNP 10_CD ,_, 1997_CD ._. It_PRP was_VBD published_VBN in_IN the_DT Federal_NNP
Register_NNP as_IN a_DT final_JJ rule_NN on_IN June_NNP 5_CD ,_, 1997_CD ._. 62_CD Fed_NNP ._. Reg_NNP ._. 30936_CD ._.
FDA_NNP is_VBZ issuing_VBG this_DT rule_NN to_TO reduce_VB the_DT risk_NN of_IN an_DT outbreak_NN of_IN
transmissible_JJ spongiform_NN encephalopathy_NN (_( TSE_NNP )_) in_IN the_DT United_NNP States_NNPS ._.
In_IN the_DT United_NNP Kingdom_NNP ,_, one_CD form_NN of_IN TSE_NNP ,_, bovine_JJ spongiform_NN
encephalopathy_NN (_( BSE_NNP )_) ,_, is_VBZ believed_VBN to_TO be_VB linked_VBN to_TO cattle_NNS feed_VBP
containing_VBG rendered_VBN protein_NN by-products_JJ from_IN sheep_NN and_CC goats_NNS
infected_VBN with_IN scrapie_NN ,_, a_DT disease_NN related_VBN to_TO BSE_NNP ._. FDA_NNP suggests_VBZ there_EX
may_MD be_VB an_DT association_NN between_IN BSE_NNP and_CC a_DT form_NN of_IN human_JJ TSE_NNP known_VBN as_IN
new_JJ variant_NN Creutzfeldt-_NNP Jakob_NNP disease_NN ._. BSE_NNP has_VBZ not_RB been_VBN diagnosed_VBN
in_IN the_DT United_NNP States_NNPS ._. This_DT rule_NN is_VBZ intended_VBN to_TO prevent_VB the_DT
establishment_NN and_CC amplification_NN of_IN BSE_NNP in_IN the_DT United_NNP States_NNPS through_IN
feed_NN and_CC ,_, thereby_RB ,_, to_TO minimize_VB the_DT risk_NN to_TO animals_NNS and_CC humans_NNS ._.
GAO_NNP /_NN OGC-_NNP 97_CD -_: 51_CD
This_DT rule_NN amends_NNS FDA_NNP regulations_NNS to_TO provide_VB that_DT animal_NN protein_NN
derived_VBN from_IN mammalian_JJ tissues_NNS for_IN use_NN in_IN ruminant_NN feed_NN is_VBZ a_DT food_NN
additive_JJ subject_NN to_TO certain_JJ provisions_NNS in_IN the_DT Federal_NNP Food_NNP ,_, Drug_NNP ,_,
and_CC Cosmetic_NNP Act_NNP (_( 21_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 301_CD et_CC seq_NN ._. )_) ._. FDA_NNP is_VBZ taking_VBG this_DT
action_NN because_IN ruminants_NNS are_VBP being_VBG fed_VBN protein_NN derived_VBN from_IN animals_NNS
in_IN which_WDT TSE_NNP has_VBZ been_VBN found_VBN and_CC such_JJ proteins_NNS may_MD cause_VB TSE_NNP in_IN
ruminants_NNS ._.
Enclosed_NNP is_VBZ our_PRP$ assessment_NN of_IN FDA_NNP 's_POS compliance_NN with_IN the_DT
procedural_JJ steps_NNS required_VBN by_IN section_NN 801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) through_IN (_( iv_NN )_)
of_IN title_NN 5_CD with_IN respect_NN to_TO the_DT rule_NN ._. Our_PRP$ review_NN indicates_VBZ that_IN FDA_NNP
complied_VBD with_IN the_DT applicable_JJ requirements_NNS ._.
If_IN you_PRP have_VBP any_DT questions_NNS about_IN this_DT report_NN ,_, please_VB contact_NN
Kathleen_NNP Wannisky_NNP ,_, Associate_NNP General_NNP Counsel_NNP for_IN Operations_NNP ,_, at_IN
(_( 202_CD )_) 512_CD -_: 5207_CD ._. The_DT official_NN responsible_JJ for_IN GAO_NNP evaluation_NN work_NN
relating_VBG to_TO the_DT Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC
Drug_NNP Administration_NNP is_VBZ Robert_NNP Robinson_NNP ,_, Director_NNP ,_, Food_NNP and_CC
Agriculture_NNP Issues_NNPS ._. Mr_NNP ._. Robinson_NNP can_MD be_VB reached_VBN at_IN (_( 202_CD )_)
512_CD -_: 5138_CD ._.
Robert_NNP P_NN ._. Murphy_NNP General_NNP Counsel_NNP
Enclosure_NNP
cc_NN :_: The_DT Honorable_NNP Donna_NNP E_NNP ._. Shalala_NNP Secretary_NNP of_IN Health_NNP and_CC Human_NNP
Services_NNPS
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 97_CD -_: 51_CD
ENCLOSURE_NNP
ANALYSIS_NNP UNDER_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN 801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) -_: (_( iv_NN )_) OF_IN A_DT MAJOR_NNP RULE_NNP
ISSUED_NNP BY_NNP THE_DT DEPARTMENT_NNP OF_IN HEALTH_NN AND_CC HUMAN_NNP SERVICES_NNS ,_, FOOD_NN AND_CC
DRUG_NNP ADMINISTRATION_NNP ENTITLED_NNP "_'' SUBSTANCES_NNP PROHIBITED_NNP FROM_NNP USE_NNP IN_IN
ANIMAL_NNP FOOD_NN OR_NNP FEED_NNP ;_: ANIMAL_NNP PROTEINS_NNP PROHIBITED_NNP IN_IN RUMINANT_NNP FEED_NNP "_''
(_( RIN_NNP :_: 0910_CD -_: AA_NN 91_CD )_)
(_( i_NNP )_) Cost-benefit_NNP analysis_NN
In_IN the_DT preamble_NN to_TO the_DT rule_NN ,_, FDA_NNP presents_VBZ a_DT summary_NN of_IN its_PRP$
economic_JJ analyses_NNS ,_, discussing_VBG the_DT potential_JJ benefits_NNS of_IN the_DT
proposed_VBN rule_NN and_CC the_DT economic_JJ impact_NN that_WDT could_MD occur_VB as_IN a_DT result_NN
of_IN its_PRP$ implementation_NN ._. Full_NNP texts_NNS of_IN both_DT the_DT cost_NN analysis_NN and_CC an_DT
addendum_NN were_VBD provided_VBN to_TO GAO_NNP at_IN the_DT time_NN the_DT agency_NN filed_VBD the_DT rule_NN
with_IN us_PRP ._. In_IN accordance_NN with_IN Executive_NNP Order_NNP 12866_CD ,_, the_DT analyses_NNS
describe_VBP the_DT regulatory_JJ options_NNS available_JJ to_TO reduce_VB the_DT risk_NN of_IN an_DT
outbreak_NN of_IN BSE_NNP in_IN the_DT United_NNP States_NNPS and_CC the_DT costs_NNS and_CC benefits_NNS
associated_VBN with_IN each_DT option_NN ._.
FDA_NNP estimates_VBZ the_DT direct_JJ compliance_NN costs_NNS of_IN the_DT rule_NN will_MD be_VB
about_IN $_$ 44_CD ._. 3_LS million_CD per_IN year_NN and_CC that_IN the_DT initial_JJ value_NN of_IN the_DT
affected_VBN meat_NN and_CC bone_NN meal_NN will_MD be_VB reduced_VBN by_IN $_$ 171_CD million_CD
annually_RB ._. In_IN contrast_NN ,_, nonruminant_NN animal_NN producers_NNS may_MD gain_VB up_IN to_TO
$_$ 162_CD million_CD in_IN lower_JJR feed_NN costs_NNS ._. FDA_NNP estimates_VBZ that_IN the_DT aggregated_JJ
net_JJ annualized_VBN costs_NNS of_IN the_DT rule_NN ,_, accounting_NN for_IN both_DT losses_NNS and_CC
gains_NNS ,_, will_MD total_VB $_$ 52_CD ._. 9_CD million_CD ._.
The_DT primary_JJ benefit_NN of_IN this_DT rule_NN ,_, as_IN described_VBN in_IN the_DT economic_JJ
analyses_NNS ,_, is_VBZ the_DT costs_NNS that_WDT would_MD be_VB averted_VBN by_IN reducing_VBG the_DT risk_NN
of_IN BSE_NNP becoming_VBG established_VBN and_CC proliferating_VBG in_IN the_DT United_NNP States_NNPS
through_IN feed_NN ._. FDA_NNP stated_VBD that_IN it_PRP could_MD not_RB quantify_VB the_DT costs_NNS of_IN
all_PDT the_DT benefits_NNS associated_VBN with_IN this_DT rule_NN ,_, such_JJ as_IN the_DT value_NN of_IN
human_JJ lives_NNS saved_VBN or_CC the_DT medical_JJ costs_NNS that_WDT would_MD be_VB avoided_VBN by_IN
preventing_VBG an_DT outbreak_NN of_IN BSE_NNP ._. However_RB ,_, it_PRP did_VBD provide_VB estimates_NNS of_IN
some_DT of_IN the_DT costs_NNS that_WDT might_MD be_VB incurred_VBN if_IN the_DT rule_NN were_VBD not_RB
implemented_VBN and_CC an_DT outbreak_NN of_IN BSE_NNP were_VBD to_TO occur_VB in_IN the_DT United_NNP
States_NNPS ._. FDA_NNP estimates_VBZ that_IN costs_NNS of_IN $_$ 93_CD million_CD would_MD be_VB incurred_VBN
in_IN direct_JJ livestock_NN losses_NNS due_JJ to_TO BSE_NNP infection_NN ,_, that_IN costs_NNS of_IN $_$ 4_CD ._. 7_CD
billion_CD would_MD be_VB incurred_VBN slaughtering_VBG at-risk_JJ cattle_NNS culled_VBN to_TO
prevent_VB BSE_NNP spread_NN ,_, and_CC that_IN costs_NNS of_IN $_$ 593_CD million_CD would_MD be_VB
incurred_VBN imposing_VBG feed_NN regulations_NNS at_IN the_DT time_NN BSE_NNP was_VBD
detected_VBN ._.
GAO_NNP /_NN OGC-_NNP 97_CD -_: 51_CD
(_( ii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO the_DT Regulatory_NNP Flexibility_NNP Act_NNP ,_,
5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 603_CD -_: 605_CD ,_, 607_CD and_CC 609_CD
On_IN January_NNP 3_CD ,_, 1997_CD ,_, FDA_NNP published_VBD a_DT summary_NN of_IN its_PRP$ Initial_JJ
Regulatory_NNP Impact_NNP Analysis_NNP in_IN the_DT preamble_NN to_TO the_DT proposed_VBN rule_NN (_( 62_CD
Fed_NNP ._. Reg_NNP ._. 552_CD at_IN 572_CD )_) ._. FDA_NNP concluded_VBD that_IN the_DT rule_NN will_MD have_VB a_DT
significant_JJ impact_NN on_IN a_DT substantial_JJ number_NN of_IN small_JJ entities_NNS ._. The_DT
vast_JJ majority_NN of_IN entities_NNS involved_VBN in_IN ruminant_NN production_NN and_CC meat_NN
preparation_NN are_VBP considered_VBN small_JJ businesses_NNS according_VBG to_TO size_NN
standards_NNS set_VBN by_IN the_DT Small_NNP Business_NNP Administration_NNP ._. The_DT analysis_NN
also_RB discusses_NNS the_DT regulatory_JJ alternatives_NNS FDA_NNP considered_VBD in_IN
drafting_VBG the_DT proposed_VBN rule_NN ._.
FDA_NNP published_VBD a_DT summary_NN of_IN its_PRP$ Final_JJ Regulatory_NNP Flexibility_NNP
Analysis_NNP in_IN the_DT preamble_NN to_TO the_DT final_JJ rule_NN published_VBN on_IN June_NNP 5_CD ,_,
1997_CD (_( 62_CD Fed_NNP ._. Reg_NNP ._. 30936_CD at_IN 30966_CD )_) ._. In_IN that_DT analysis_NN FDA_NNP discusses_NNS
the_DT need_NN for_IN the_DT rule_NN ,_, the_DT benefits_NNS anticipated_VBN from_IN the_DT
implementation_NN of_IN the_DT rule_NN ,_, and_CC a_DT summary_NN of_IN the_DT impacts_NNS of_IN the_DT
final_JJ rule_NN ._. The_DT preamble_NN summarizes_NNS the_DT issues_NNS raised_VBN by_IN the_DT public_JJ
comments_NNS to_TO the_DT proposed_VBN rule_NN ,_, describes_VBZ the_DT numbers_NNS of_IN small_JJ
entities_NNS affected_VBN by_IN the_DT rule_NN ,_, and_CC describes_VBZ the_DT recordkeeping_NN
burden_NN of_IN the_DT rule_NN ._. The_DT preamble_NN also_RB describes_VBZ the_DT seven_CD
alternatives_NNS considered_VBN by_IN FDA_NNP in_IN promulgating_VBG this_DT rule_NN and_CC why_WRB it_PRP
believes_VBZ that_IN the_DT alternative_NN selected_VBN (_( the_DT mammalian-to-ruminant_JJ
prohibition--with_JJ exceptions_NNS )_) is_VBZ the_DT most_RBS cost-effective_JJ regulatory_JJ
alternative_NN that_WDT meets_VBZ the_DT objective_NN of_IN the_DT agency_NN ._. FDA_NNP also_RB points_VBZ
out_RP that_IN it_PRP revised_VBD the_DT rule_NN in_IN several_JJ respects_VBZ to_TO decrease_VB the_DT
burden_NN on_IN small_JJ entities_NNS in_IN response_NN to_TO comments_NNS received_VBD from_IN
small_JJ businesses_NNS ._.
(_( iii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO sections_NNS 202_CD -_: 205_CD of_IN the_DT
Unfunded_NNP Mandates_NNP Reform_NNP Act_NNP of_IN 1995_CD ,_, 2_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 1532_CD -_: 1535_CD
FDA_NNP determined_VBD that_IN ,_, because_IN this_DT rule_NN imposes_VBZ no_DT mandates_VBZ on_IN
government_NN entities_NNS and_CC will_MD result_VB in_IN expenditures_NNS of_IN less_JJR that_IN
$_$ 100_CD ,_, 000_CD ,_, 000_CD in_IN any_DT one_CD year_NN ,_, that_IN no_DT further_JJ analysis_NN is_VBZ needed_VBN
under_IN the_DT Unfunded_NNP Mandates_NNP Reform_NNP Act_NNP ._.
(_( iv_NN )_) Other_JJ relevant_JJ information_NN or_CC requirements_NNS under_IN acts_NNS and_CC
executive_NN orders_NNS
Administrative_NNP Procedure_NNP Act_NNP ,_, 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 551_CD et_CC seq_NN ._.
This_DT rule_NN was_VBD published_VBN as_IN a_DT notice_NN of_IN proposed_VBN rulemaking_VBG on_IN
January_NNP 3_CD ,_, 1997_CD (_( 62_CD Fed_NNP ._. Reg_NNP ._. 552_CD )_) under_IN the_DT notice_NN and_CC comment_VB
procedures_NNS of_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN 553_CD ._. Based_VBN on_IN the_DT numerous_JJ comments_NNS it_PRP
received_VBD ,_, FDA_NNP published_VBD the_DT codified_VBN provisions_NNS of_IN the_DT draft_NN final_JJ
rule_NN on_IN April_NNP 17_CD ,_, 1997_CD (_( 62_CD Fed_NNP ._. Reg_NNP ._. 18728_CD )_) and_CC provided_VBD an_DT
opportunity_NN for_IN the_DT public_NN to_TO comment_VB ._. FDA_NNP made_VBD some_DT changes_NNS to_TO the_DT
draft_NN language_NN based_VBN on_IN those_DT comments_NNS and_CC published_VBD the_DT final_JJ rule_NN
on_IN June_NNP 5_CD ,_, 1997_CD (_( 62_CD Fed_NNP ._. Reg_NNP ._. 30936_CD )_) ._. The_DT preamble_NN to_TO the_DT final_JJ
rule_NN discusses_NNS the_DT comments_NNS received_VBD and_CC the_DT actions_NNS taken_VBN upon_IN
them_PRP ._.
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 97_CD -_: 51_CD
Paperwork_NNP Reduction_NNP Act_NNP ,_, 44_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 3501_CD -_: 3520_CD
This_DT final_JJ rule_NN contains_VBZ information_NN collection_NN requirements_NNS
which_WDT are_VBP subject_JJ to_TO the_DT Paperwork_NNP Reduction_NNP Act_NNP ._. FDA_NNP submitted_VBD the_DT
information_NN collection_NN request_NN to_TO OMB_NNP for_IN approval_NN at_IN the_DT time_NN the_DT
proposed_VBN rule_NN was_VBD published_VBN (_( January_NNP 3_CD ,_, 1997_CD )_) ._. OMB_NNP did_VBD not_RB approve_VB
the_DT information_NN collection_NN as_IN submitted_VBN ,_, but_CC required_VBD FDA_NNP to_TO invite_VB
comments_NNS on_IN the_DT information_NN collection_NN when_WRB the_DT final_JJ rule_NN was_VBD
published_VBN ._. After_IN FDA_NNP evaluates_VBZ the_DT comments_NNS received_VBD ,_, makes_VBZ any_DT
revisions_NNS ,_, and_CC receives_VBZ final_JJ OMB_NNP approval_NN for_IN the_DT information_NN
collection_NN ,_, FDA_NNP will_MD announce_VB in_IN the_DT Federal_NNP Register_NNP that_DT approval_NN
and_CC the_DT effective_JJ date_NN of_IN the_DT part_NN of_IN the_DT regulations_NNS that_WDT relate_VBP
to_TO the_DT information_NN collection_NN ._.
Executive_NNP Order_NNP 12866_CD
This_DT final_JJ rule_NN is_VBZ considered_VBN to_TO be_VB an_DT "_'' economically_RB significant_JJ
regulatory_JJ action_NN "_'' under_IN Executive_NNP Order_NNP 12866_CD ._. In_IN accordance_NN with_IN
the_DT provisions_NNS of_IN the_DT executive_NN order_NN ,_, FDA_NNP assessed_VBD the_DT costs_NNS and_CC
benefits_NNS of_IN regulatory_JJ alternatives_NNS and_CC appears_VBZ to_TO have_VB selected_VBN
the_DT approach_NN that_WDT maximizes_NNS net_JJ benefits_NNS while_IN still_RB meeting_VBG agency_NN
objectives_NNS ._.
Executive_NNP Order_NNP 12612_CD
FDA_NNP states_NNS that_IN it_PRP has_VBZ analyzed_VBN this_DT rule_NN in_IN accordance_NN with_IN the_DT
principles_NNS set_VBN forth_RB in_IN Executive_NNP Order_NNP 12612_CD ,_, Federalism_NNP ,_, and_CC has_VBZ
determined_VBN that_IN the_DT rule_NN does_VBZ not_RB warrant_VB the_DT preparation_NN of_IN a_DT
Federalism_NNP Assessment_NNP ._.
Statutory_NNP authorization_NN for_IN the_DT rule_NN
FDA_NNP cites_VBZ sections_NNS 201_CD ,_, 402_CD ,_, 403_CD ,_, 409_CD ,_, and_CC 701_CD of_IN the_DT Federal_NNP
Food_NNP ,_, Drug_NNP ,_, and_CC Cosmetic_NNP Act_NNP (_( 21_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 321_CD ,_, 342_CD ,_, 343_CD ,_, 348_CD ,_, and_CC
721_CD )_) as_IN statutory_JJ authority_NN for_IN this_DT rule_NN ._.
Page_NNP 3_CD GAO_NNP /_NN OGC-_NNP 97_CD -_: 51_CD



